Janssen Targets Combinations As Next Step For Newly Approved Darzalex

Johnson and Johnson company, Janssen Research and Development, believes it can take its newly approved multiple myeloma therapy Darzalex (daratumumab) one step further by combining it with Revlimid (lenalidomide) and dexamethasone.